Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Evaluation of Three Neuromuscular Electrical Stimulation Foot Pad Programmes on Lower Limb Haemodynamics in Healthy Adults (TRI-HEX)

25. června 2026 aktualizováno: Joey Porter

Evaluation of Lower Limb Haemodynamics Using Three (TRI) Neuromuscular Electrical Stimulation Foot Pad Programmes: A Crossover (X) Randomised Controlled Study in Healthy (HE) Adults

The goal of this clinical investigation is to evaluate the performance of three neuromuscular electrical stimulation (NMES) foot pad programmes in healthy adults. It will also learn about how well the NMES programmes are tolerated.

The main questions it aims to answer are:

  • Do two newly-developed NMES programmes ('P1' and 'PM7') increase lower limb blood flow more than the existing 'Medic' NMES programme during use?
  • How do the programmes compare in terms of user discomfort and muscle oxygenation during use?

Researchers will compare the P1 and PM7 programmes with the existing Medic programme to determine whether the new programmes produce greater improvements in lower limb haemodynamics during device use.

Participants will:

  • Attend four study visits at a single research site.
  • Complete 1 familiarisation visit and 3 testing visits, with 12 hours to 7 days between visits.
  • Use all three NMES programmes once in a randomised order.
  • Receive 30 minutes of NMES during each testing visit.
  • Undergo blood flow and muscle oxygenation measurements during each test.
  • Complete questionnaires about discomfort and their experience using the device.

Přehled studie

Postavení

Zatím nenabíráme

Podmínky

Detailní popis

The TRI-HEX study is a single-centre, randomised, double-blind, crossover clinical investigation evaluating the haemodynamic performance of three neuromuscular electrical stimulation (NMES) foot pad programs delivered through an investigational version of the Revitive device platform. The study will recruit 24 healthy adult participants in the United Kingdom.

Revitive is a non-invasive NMES device designed to improve blood circulation in the lower limbs during use. The investigational device (14065AT) is derived from the commercially available Revitive Medic Coach device and incorporates firmware modifications that enable delivery of additional predefined stimulation programmes for research purposes. The modification does not alter the device's intended purpose, mode of action, hardware, materials, or electrical output limits.

The study will evaluate three NMES programmes:

Medic - the currently marketed Revitive NMES foot pad programme. Programme 1 (P1) - a newly developed stimulation program designed to minimise muscle adaptation during use.

Personalised Medic v7 (PM7) - a stimulation programme that incorporates a personalised modulation function intended to optimise haemodynamic response.

The primary objective is to compare the effect of P1 and PM7 against the Medic programme on lower limb blood volume flow during a single 30-minute NMES session. Blood volume flow will be measured at the superficial femoral artery using Doppler ultrasound.

Secondary objectives are to compare:

User discomfort during stimulation using a visual analogue scale (VAS). Changes in muscle oxygen saturation (SmO2) measured by near-infrared spectroscopy (NIRS).

Exploratory objectives include assessment of:

Time averaged mean velocity (TAMV) at the superficial femoral artery. Changes in superficial femoral artery diameter. Post-stimulation recovery of muscle oxygenation. Relationships between haemodynamic outcomes and device-recorded accelerometry data.

Relationships between haemodynamic outcomes and skin hydration measurements.

The study uses a double-blinded crossover design, where each participant receives all three interventions in a randomised sequence and both participants and the Chief Investigator remain blinded to intervention allocation. Randomisation is performed using a predefined crossover allocation schedule, and an independent unblinded assessor is responsible for treatment sequence management.

Participants will attend four visits:

Visit 1: eligibility confirmation, informed consent, device familiarisation, collection of baseline demographic and lifestyle information, and a motion analysis baseline assessment.

Visits 2-4: completion of one 30-minute NMES session per visit using one of the three study programmes, with a washout period of 12 hours to 7 days between sessions.

During each testing visit, participants will undergo a 10-minute baseline measurement period, followed by a 30-minute NMES session and 8-minute post-stimulation monitoring. Doppler ultrasound and NIRS measurements will be collected throughout the assessment period. Participants will also complete questionnaires regarding discomfort and device experience.

The study is designed as an exploratory clinical investigation to generate haemodynamic performance data on newly developed NMES stimulation programmes under controlled conditions. Results will be used to assess differences in haemodynamic performance between the investigational programmes and to support future product development and evidence generation activities.

Typ studie

Intervenční

Zápis (Odhadovaný)

24

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní záloha kontaktů

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

  • Dospělý
  • Starší dospělý

Přijímá zdravé dobrovolníky

Ano

Popis

Inclusion Criteria:

  • Healthy
  • Age 18 or over
  • Ability to communicate in English and provide informed consent

Exclusion Criteria:

  • Lack of capacity to provide informed consent
  • Electronic implanted device (e.g. cardiac pacemaker)
  • Pregnancy or intending to become pregnant during the study period
  • Currently being treated for or have symptoms of an existing deep vein thrombosis (DVT)
  • Diagnosis of vascular disease or disorder
  • Terminal illness
  • Neurological disorders (e.g. epilepsy)
  • Musculoskeletal injury/disorders (e.g. recent injury or surgery)
  • Skin conditions (e.g. eczema or open wounds near plantar surface of the foot)
  • Cardiovascular conditions (e.g. arrhythmia or uncontrolled hypertension)
  • Diabetes mellitus with neuropathy.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Základní věda
  • Přidělení: Randomizované
  • Intervenční model: Crossover Assignment
  • Maskování: Dvojnásobek

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Aktivní komparátor: Medic
Participants receive the Medic programme delivered via the investigational medical device. This arm consists of a single 30-minute neuromuscular electrical stimulation session.
The Medic programme is a currently marketed neuromuscular electrical stimulation (NMES) foot pad programme. It delivers electrical stimulation through the soles of the feet, via a commercially available NMES medical device, to induce lower limb muscle contractions and improve blood circulation during use.
Ostatní jména:
  • Medic programme
Experimentální: P1
Participants receive the Programme 1 (P1) delivered via the investigational medical device. This arm consists of a single 30-minute neuromuscular electrical stimulation session.
Programme 1 (P1) is an investigational NMES foot pad programme that incorporates a modified stimulation pattern designed to reduce muscle adaptation during a 30-minute stimulation session while maintaining the same intended purpose and mode of action as the marketed programme.
Ostatní jména:
  • Programme 1
Experimentální: PM7
Participants receive the PM7 programme delivered via the investigational medical device. This arm consists of a single 30-minute neuromuscular electrical stimulation session.
Personalised Medic v7 (PM7) is an investigational NMES foot pad programme that incorporates a modulation function intended to optimise the haemodynamic response during stimulation while maintaining the same intended purpose and mode of action as the marketed programme.
Ostatní jména:
  • Personalised Medic Programme v7

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in blood volume flow at the superficial femoral artery (SFA)
Časové okno: Throughout a 10-minute baseline, the 30-minute stimulation session and 8-minute post-stimulation period.
Change in blood volume flow from baseline at the superficial femoral artery during a single 30-minute neuromuscular electrical stimulation (NMES) programme. Blood volume flow will be measured using Doppler ultrasound and compared between the Medic, P1, and PM7 NMES programmes.
Throughout a 10-minute baseline, the 30-minute stimulation session and 8-minute post-stimulation period.

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in muscle oxygen saturation (SmO2) at the medial gastrocnemius
Časové okno: Throughout a 10-minute baseline, the 30-minute stimulation session and 8-minute post-stimulation period.
Change in muscle oxygen saturation from baseline at the medial head of the gastrocnemius during a single 30-minute NMES programme. SmO2 will be measured using Near-Infrared Spectroscopy (NIRS) and compared between the Medic, P1, and PM7 programmes.
Throughout a 10-minute baseline, the 30-minute stimulation session and 8-minute post-stimulation period.
Discomfort during NMES stimulation
Časové okno: During the 30-minute stimulation session
Participant-reported discomfort assessed using an 11-point Visual Analogue Scale (VAS, 0-10, higher scores indicate greater discomfort) during a single 30-minute NMES session. Scores will be compared between the Medic, P1, and PM7 programmes. Participants will report their VAS score immediately after completion of the test period and will refer to their experience over the whole 30-minute programme.
During the 30-minute stimulation session

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Vyšetřovatelé

  • Vrchní vyšetřovatel: Joey Porter, Actegy Ltd.

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

6. července 2026

Primární dokončení (Odhadovaný)

1. ledna 2027

Dokončení studie (Odhadovaný)

1. ledna 2027

Termíny zápisu do studia

První předloženo

19. června 2026

První předloženo, které splnilo kritéria kontroly kvality

19. června 2026

První zveřejněno (Aktuální)

24. června 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

29. června 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

25. června 2026

Naposledy ověřeno

1. června 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • 26/WM/0029

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Popis plánu IPD

Individual participant data (IPD) will not be shared because this is an early feasibility, manufacturer-sponsored exploratory investigation with a small sample size (n=24). Due to the limited study population and the potential risk of participant re-identification, de-identified participant-level datasets will not be made publicly available. Aggregate study results will be reported through ClinicalTrials.gov and any resulting scientific publications.

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit